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Purpose: Urinary incontinence (UI) following prostate radiotherapy is a rare toxicity that adversely affects a patient’s
quality of life. This study sought to evaluate the incidence of UI following stereotactic body radiation therapy (SBRT)
for prostate cancer.
Methods: Between February, 2008 and October, 2010, 204 men with clinically localized prostate cancer were
treated definitively with SBRT at Georgetown University Hospital. Patients were treated to 35–36.25 Gray (Gy) in 5
fractions delivered with the CyberKnife (Accuray). UI was assessed via the Expanded Prostate Index Composite
(EPIC)-26.
Results: Baseline UI was common with 4.4%, 1.0% and 3.4% of patients reporting leaking > 1 time per day, frequent
dribbling and pad usage, respectively. Three year post treatment, 5.7%, 6.4% and 10.8% of patients reported UI
based on leaking > 1 time per day, frequent dribbling and pad usage, respectively. Average EPIC UI summary scores
showed an acute transient decline at one month post-SBRT then a second a gradual decline over the next three
years. The proportion of men feeling that their UI was a moderate to big problem increased from 1% at baseline to
6.4% at three years post-SBRT.
Conclusions: Prostate SBRT was well tolerated with UI rates comparable to conventionally fractionated radiotherapy
and brachytherapy. More than 90% of men who were pad-free prior to treatment remained pad-free three years
following treatment. Less than 10% of men felt post-treatment UI was a moderate to big problem at any time
point following treatment. Longer term follow-up is needed to confirm late effects.
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Quality of lifeBackground
Involuntary leakage of urine is a common problem of aging.
Urinary incontinence (UI) varies in frequency and severity,
making it clinically challenging to define. In men greater
than sixty five years old, the prevalence of UI may be as
high is 31% [1]. UI is caused by an overactive bladder (urge
incontinence) and/or poor urethral sphincter function* Correspondence: SPC9@gunet.georgetown.edu
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unless otherwise stated.(stress incontinence) [2]. Aging, comorbidities, obesity, be-
nign prostatic hypertrophy, prostate cancer and its treat-
ments may increase the risk of UI [3]. Urinary continence
recovery following radical prostatectomy is variable with
5-30% of patients still requiring pads one year after surgery
[4,5]. The incidence of UI after external beam radiation
therapy or brachytherapy varies considerably with a re-
ported range of 10% to 30% [6-9]. The incidence of UI is
dependent on the definition utilized [10] and on the man-
ner of data collection (i.e. patient or physician reported)
[11]. Post-treatment UI develops months to years after radi-
ation therapy without recovery [8,9] and may adverselytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[12]. Bother from UI varies based on its severity [13,14]. UI
is commonly refractory to treatment [15] and the daily
usage of pads is a burden for patients and caregivers [16].
Clinical data suggest that hypofractionated radiation
therapy may be radiobiologically favorable to smaller frac-
tion sizes in prostate cancer radiotherapy [17]. The α/β for
prostate cancer may be as low as 1.5 Gy (Gray) [17]. If the
α/β for prostate cancer is less than 3 Gy, which is gener-
ally the value accepted for late urinary complications, the
linear-quadratic model predicts that delivering large radi-
ation fraction sizes will result in improved local control
with a similar rate of urinary complications. Early data
from trials of limited hypofractionation (fraction sizes
from 2.5 to 3.5 Gy) revealed that such regimens are effect-
ive without undue urinary toxicity [18].
Stereotactic body radiation therapy (SBRT) uses even
larger daily fractions of radiation (7–9 Gy) to take fur-
ther advantage of this postulated radiobiological advan-
tage. Emerging clinical data suggest that this approach
may provide similar clinical outcomes as other radiation
modalities with high rates of biochemical control and
low rates of grade 3 and higher toxicities [19-25]. Based
on patient preference for a shorter treatment course,
SBRT utilization is likely to increase as long as toxicity is
acceptable. Here, we present our institutional patient-
reported urinary incontinence rates following SBRT for
clinically localized prostate cancer.
Methods
Patient selection
Patients eligible for study inclusion had histologically-
confirmed prostate cancer treated per our institutional
protocol. Prospectively collected quality of life (QoL)
data for all patients included in our institutional data-
base were retrospectively analyzed with Georgetown
University Internal Review Board (IRB) approval.
SBRT treatment planning and delivery
SBRT treatment planning and delivery were conducted
as previously described [22,26]. Four gold markers were
placed into the prostate. Several days after marker place-
ment, patients underwent magnetic resonance (MR)
imaging followed shortly thereafter by a computed tom-
ography (CT) scan. Fused CT and MR images were used
for treatment planning. The clinical target volume
(CTV) included the prostate and the proximal seminal
vesicles. The planning target volume (PTV) equaled the
CTV expanded 3 mm posteriorly and 5 mm in all other
dimensions. The prescription dose was 35–36.25 Gy to
the PTV delivered in five fractions of 7–7.25 Gy corre-
sponding to a tumor equivalent dose in 2-Gy fractions
(EQD2) of approximately 85–90 Gy assuming an alpha/
beta ratio of 1.5. The bladder and membranous urethrawere contoured and evaluated with dose-volume histo-
gram analysis during treatment planning using Multi-
plan (Accuray Inc., Sunnyvale, CA) inverse treatment
planning as previously defined. The dose-volume histo-
gram (DVH) goals were for < 50% membranous urethra
and < 5 cc of the bladder receiving 37 Gy. To minimize
the risk of local recurrence, the dose to the prostatic
urethra was not constrained [27]. Target position was
verified multiple times during each treatment using
paired, orthogonal x-ray images [28].
Follow-up and statistical analysis
Patients completed the Short Form-12 Health Survey (SF-12)
[29], the American Urological Association Symptom
Index (AUA) [30] and Expanded Prostate Cancer Index
Composite (EPIC)-26 [31] before treatment and during
routine follow-up visits one month after the completion of
SBRT, every 3 months for the first year and then every
6 months for the second and third years. UI was assessed
via the urinary incontinence domain of the Expanded
Prostate Index Composite (EPIC)-26 [31]. The EPIC-26
UI domain includes three questions related to function
(Questions 1–3 of the EPIC-26) and one question related
to bother (Question 4 of the EPIC-26). The functions
assessed included UI frequency, urinary control and pad
usage [32]. For each EPIC question, the responses were
grouped into three to four clinically relevant categories.
UI rates were defined using three separate commonly
employed definitions: leaking > one time per day, frequent
dribbling and daily pad usage [8]. To statistically compare
changes between time points, the levels of responses were
assigned a score and the significance of the mean changes
in the scores was assessed by paired t test.
EPIC summary scores for the UI domain range from
0–100 with lower values representing worsening UI. The
minimally important difference (MID) in EPIC score was
defined as a change of one-half standard deviation (SD)
from the baseline [33]. The EPIC UI domain summary
scores were stratified to three levels of severity as previ-
ously described [34]: severe (0–49), moderate (50–69)
and mild (70–100). Multiple logistic regression with
backward elimination was used in the multivariate ana-
lysis to search for possible predicting factors for UI. The
endpoint for this analysis was the EPIC UI subdomain
score at 3 years post-SBRT. Baseline characteristics in-
cluding age, prostate volume, α1A inhibitor usage, and
AUA scores were included as variables in the logistic re-
gression model.
Results
From February 2008 to October 2010, 204 prostate can-
cer patients were treated per our institutional SBRT
monotherapy protocol (Table 1). The median follow-up
was 3.9 years. They were ethnically diverse with 45.6%
Table 1 Baseline patient characteristics and treatment
Patients (N=204)
Age (y/o) Median 69 (48~90)
Age ≤ 60 12.7%
60 < Age ≤ 70 46.6%




Charlson Comorbidity Index CCI=0 65.2%
CCI=1 21.1%
CCI≥2 13.7%
Body Mass Index (BMI) Median 27.60
(15.02-44.96)
BMI ≥ 30 30.5%
Partner Status Married or Partnered 76.0%
Not Partnered 24.0%
Employment Status Working 48.0%
Not Working 52.0%
Median Prostate Volume (cc) Median 39
(11.6-138.7) cc
Procedure for BPH 7.8%
α1A inhibitor usage 27.9%




SBRT Dose 36.25 Gy 88.2%
35 Gy 11.8%
Table 2 Pre-treatment Quality of Life (QOL) scores
(n=204)
Baseline AUA Score % Patients
0-7 (mild) 50.0%
8-19 (moderate) 43.6%
≥ 20 (Severe) 6.4%
Baseline SF-12 Score Mean (Range) SD
PCS (Physical Health Score) 49.9 (15.6-64.4) 8.76
MCS (Mental Health Score) 56.6 (27.2-69.5) 6.71
Baseline EPIC-26
Incontinence Score
Mean (Range) SD MID
Bother 92.5 (25-100) 14.79 7.4
Summary 92.3 (18.8-100) 13.99 7.0
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69 years (range, 48–90 years). Obesity and comorbidities
were common. 50% of patients had moderate to severe
lower urinary tract symptoms prior to treatment (base-
line AUA ≥ 8) with a median baseline AUA of 7.5
(Table 2). The median prostate volume was 39 (11.6-
138.7) cc and 7.8% had prior procedures for benign
prostatic hyperplasia (BPH). 27.9% of patients utilized
alpha-antagonists prior to SBRT. By D’Amico classifica-
tion, 81 patients were low-, 106 intermediate-, and 17
high-risk. Twenty nine patients (14.2%) also received an-
drogen deprivation therapy (ADT) with median duration
of 3 months (range, 3–24 mon). 88.2% of the patients
were treated with 36.25 Gy in five 7.25 Gy fractions.
Baseline UI was common in our patients. Prior to treat-
ment, 4.4% of the patients reporting leaking once per day
or more and 1% reported frequent dribbling or no control
at all (Table 3, Figure 1). Unexpectedly, 3.5% of patients
reported using one or more pads per a day prior to SBRT
(Table 3, Figure 1). At three year post treatment, 5.7%,6.4% and 10.8% of patients reported incontinence based
on the definitions of leaking > one time per day, frequent
dribbling and pad usage, respectively (Table 3, Figure 1).
However, only 1.9% reported no control of urination and
only 4.5% reported using more than one pad per a day
(Table 3). The increase in pad usage was unlikely solely
due to aging, as the mean age of pad-using patients at
36 months (73.8 y/o) was not statistically different from
non-pad using patients (71.3 y/o) (p = 0.106).
Treatment-related bother may be more important to an
individual patient than treatment-related dysfunction. At
baseline, 24.2% of our cohort reported some level of bother
due to urinary dripping or leaking with 1.0% of the patients
feeling it was a moderate to big problem (Table 3, Figure 2a).
The baseline UI bother score is shown in Table 2 and mean
changes in EPIC UI bother scores from baseline to 3 years
of follow-up are shown in Table 4. The mean EPIC UI
bother score was 92.5 at baseline (Table 2). UI bother in-
creased following treatment with the mean score decreasing
to 86.8 at 1 month post-treatment (mean change, −5.69)
(p < 0.0001) (Table 4, Figure 2b). However, only 2.5% of
patients felt that that was a moderate to big problem at
1 month following treatment (Table 3, Figure 2a). Although
UI bother improved quickly, a second late worsening in UI
bother was observed with the mean UI bother score
decreasing to 84.55 at 36 months (mean change from base-
line, −7.93) (p < 0.0001) (Table 4, Figure 2b). Only the
decline at 36 months met the threshold for clinically signifi-
cant change (MID =7.4). The proportion of men feeling that
their UI was a moderate to big problem increased to 6.4% at
three years post-SBRT (Table 3, Figure 2a).
There is no universally-accepted definition for UI and
commonly employed definitions based on responses to in-
dividual questions do not fully assess the clinical impact of
the problem (i.e., symptom, dysfunction and bother). Do-
main summary scores more comprehensively assess the
clinical impact of UI on the patient [31]. The baseline
EPIC UI summary score is shown in Table 2 and mean
Table 3 Urinary Incontinence following SBRT for prostate cancer: patient-reported responses to EPIC-26 questions 1
(frequency of leakage), 2 (urinary control), 3 (pad usage), 4a (dripping or leaking urine) and UI domain scores
Start 1 M 6 M 12 M 18 M 24 M 30 M 36 M
N= 204 200 186 178 165 175 171 157
Frequency of leakage
Never leak 79.3% 69.5% 69.9% 69.1% 69.7% 68.0% 65.5% 64.3%
Leak ≤ 1 time/day 16.3% 24.0% 27.4% 27.5% 24.2% 24.6% 29.8% 29.9%
Leak >1 time/day 4.4% 6.5% 2.7% 3.4% 6.1% 7.4% 4.7% 5.7%
Urinary Control
Total Control 72.9% 61.8% 61.8% 54.8% 57.6% 65.1% 59.1% 57.3%
Occasional dribbling 26.1% 35.2% 34.9% 41.2% 37.0% 31.4% 34.5% 36.3%
Frequent dribbling 0.0% 2.0% 1.6% 1.7% 3.0% 3.4% 5.8% 4.5%
No control 1.0% 1.0% 1.6% 2.3% 1.8% 0.0% 0.6% 1.9%
Pad Usage
No pads 96.6% 92.5% 95.7% 92.7% 91.5% 92.0% 90.1% 89.2%
1 pad/day 3.0% 5.5% 3.2% 5.1% 6.1% 5.1% 6.4% 6.3%
≥ 2 pads/day 0.5% 2.0% 1.1% 2.2% 2.4% 2.9% 3.5% 4.5%
Bother-dripping/leaking
No problem 75.9% 62.9% 68.3% 61.8% 64.2% 60.6% 60.8% 58.0%
Small problem 23.2% 34.5% 30.1% 34.8% 29.7% 33.7% 34.5% 35.7%
Mod-Big problem 1.0% 2.5% 1.6% 3.4% 6.1% 5.7% 4.7% 6.4%
UI Domain
Mild (70-100) 90.1% 85.5% 86.6% 84.8% 81.8% 85.1% 83.6% 84.7%
Moderate (50-69) 7.4% 11.0% 11.8% 12.4% 14.5% 9.1% 11.1% 8.3%
Severe (0-49) 2.5% 3.5% 1.6% 2.8% 3.6% 5.7% 5.3% 7.0%
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3 years of follow-up are shown in Table 4. At baseline,
10% of our cohort had moderate to severe UI (Table 3,
Figure 3a). The mean EPIC UI summary score was 92.3 at
baseline (Table 2). The EPIC UI summary score declined
acutely at 1 month post-SBRT (mean change, −4.09)
(Table 5, Figure 3b). However, only 14.5% of patients had
moderate to severe UI (Table 3, Figure 3a). The EPIC UI
summary score returned to near baseline by three months
post-SBRT (mean change from baseline, −1.84) (Table 4,
Figure 3b). This acute decline was statistically (p < 0.0001)
but not clinically significant (MID = 7). Average EPIC UI
summary scores showed a second late protracted decline
over the next three years (Table 4, Figure 3b). At three
years post-treatment, the mean summary score decreased
from a baseline of 92.31 to 85.85 (mean change from base-
line at 36 months, −6.46) (Table 4). This change was sta-
tistically (p < 0.0001) but of borderline clinical significance
(MID = 7). The proportion of men with moderate to se-
vere UI increased to 15.3% at three years post-SBRT
(Table 3, Figure 3a).
When modeled with EPIC UI scores at 3 years post-
SBRT, age was not highly correlated with the UI outcome(p = 0.2671, Table 5). From a bivariate relationship, pros-
tate volume and α1A antagonist usage are highly associ-
ated with the outcome, although after adjusting for age,
only the prostate volume was highly associated with UI
score (p = 0.0091, Table 5). No other baseline patient char-
acteristics were significantly associated with UI score at
three years following SBRT.
Discussion
Urinary incontinence following prostate cancer treatment
is common [35] and an important quality of life issue [8].
A better understanding of the risk of UI following SBRT
enables clinicians to provide more realistic expectations to
patients as they weigh complex treatment options [36].
Currently, there is limited data on incidence of UI follow-
ing SBRT for prostate cancer [22]. Previously, we reported
a 10-15% risk of UI following SBRT. However, these find-
ings relied on physician reported UI rates, which may
under report the actual incidence of UI and provided no
information on the associated bother [11]. In this study,
we utilized the urinary incontinence domain of the
EPIC-26 to comprehensively evaluate patient reported



















Leak more than once a day
Frequent dribbling
Any pad use
Figure 1 Differences in rates of urinary incontinence based on definition. Percentage of patients with leakage > 1 time a day, frequent
dribbling or daily pad usage.
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pending on the definition utilized [10]. In the absence of
a consensus definition of UI, direct comparison between
treatment techniques remains difficult. The most com-
monly used definition of UI is daily pad usage [37]; how-























Figure 2 Bother with dripping or leaking at baseline and following SB
were stratified to three groups: no problem, very small-small problem and
each time point is depicted in the bar chart. (b) Average EPIC bother with
cancer. Thresholds for clinically significant changes in scores (½ standard d
EPIC scores range from 0–100 with higher values representing a more favoLikewise, men using only one pad per day may be using it
due to frequent leakage or as a precaution [32,38-40]. Thus
for this analysis, we evaluated the three commonly used
definitions to assess the incidence and associated
dysfunction. In addition, we examined the bother asso-
























RT for prostate cancer- Question 4 of the EPIC-26. (a) Patients
moderate-big problem. The percentage of patients in each group at
dripping or leaking scores at baseline and following SBRT for prostate
eviation above and below the baseline) are marked with dashed lines.
rable health-related QOL.




























UI Bother -5.69 19.65 < 0.0001 -3.35 18.74 0.007 -6.11 20.08 < 0.0001 -7.2 22.93 < 0.0001 -7.93 22.56 < 0.0001
UI Summary -4.09 16.74 < 0.0001 -1.84 14.99 0.065 -4.77 16.35 < 0.0001 -4.69 18.47 < 0.001 -6.46 19.45 < 0.0001
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elderly with poor baseline urinary function and a high
prevalence of UI prior to treatment [8]. At one month
post-treatment there was an acute increase in UI that re-
solved by three months post SBRT. This acute increase
was likely secondary to transient cystitis/urethritis, which
when moderate to severe may cause urge incontinence
[41]. As observed previously following treatment with al-
ternative radiation modalities [8,9,42,43], a second gradual
increase in UI occurred from 3 months to the end of
follow-up without recovery. Even so, by three years post-
SBRT, only 6% of these patients reported leaking more
than once per day and only 5% reported needing more
than one pad per day. Despite the high biologically effect-
ive dose (BED) delivered by SBRT in this series, these re-
sults seem similar to conventionally fractionated EBRT,
proton therapy and brachytherapy [8,44]. It seems to be
that despite the fact that patients in this study are older
and have more comorbidities, the incontinence rates com-























Figure 3 EPIC Urinary Incontinence Domain. (a) Patients were stratified
(b) Average EPIC urinary incontinence domain scores at baseline and follow
changes in scores (½ standard deviation above and below the baseline) ar
values representing a more favorable health-related QOL.The etiology of late UI following prostate cancer radi-
ation therapy appears to be multi-factorial [35], and is
likely due in part to aging and related comorbidities
[42]. Prostate cancer itself may impair the integrity of
the anatomic structures that maintain urinary contin-
ence. When compared to their peers without prostate
cancer, even men who choose active surveillance are at
increased risk of UI [37,45,46]. Previous studies of alter-
native radiation modalities have also reported that late
toxicity following radiation therapy is associated with
pretreatment factors related to BPH, such as a high
AUA score [47,48] and a large prostate volume [49].
Post-RT TURP may increase the incidence of urinary in-
continence [50]. In this series, late UI secondary to post-
RT TURP was rare. The one patient who experienced
this had a history of benign prostatic hypertrophy with a
large prostate and two prior TURP procedures prior to
receiving SBRT [22].
Compared with urinary function, bother may be a





























to three groups: severe (0–49), moderate (50–69) and mild (70–100).
ing SBRT for prostate cancer. Thresholds for clinically significant
e marked with dashed lines. EPIC scores range from 0–100 with higher
Table 5 Impact of baseline characteristics on EPIC-UI
score three years post-SBRT
Model with age and prostate volume
Estimate Standard error t Value Pr > |t|
Intercept 111.57196 15.64089521 7.13 < 0.0001
Age -0.254749 0.22871957 -1.11 0.2671
Prostate Volume -0.198787 0.07516895 -2.64 0.0091
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gree of interference or annoyance caused by urinary in-
continence, bother is dependent on an individual’s
pretreatment function [51,52]. In general, previously
continent men report higher rates of post-treatment
bother. In this series of men, UI bother gradually in-
creased during the first three years following SBRT treat-
ment (Figure 2, Table 4). Two years following SBRT, 6%
of men reported UI bother as a moderate to big prob-
lem. This change is comparable to that reported at
24 months with conventionally fractionated IMRT (5%),
proton therapy (4%) and brachytherapy (6%) [8,44].
Commonly employed UI definitions based on answers to
single questions do not fully assess the clinical impact of
urinary incontinence (i.e., symptom, dysfunction and
bother). Domain summary scores more comprehensively
assess the clinical impact of UI on the patient [31]. Our
EPIC UI summary domain outcomes appear similar to
those previously reported for high dose conventionally
fractionated intensity modulated radiation therapy
(IMRT)/proton therapy and brachytherapy [8,9]. The
mean urinary incontinence score change from baseline
at 24 months was – 4.7. This change from baseline was
statistically significant but not clinically significant. Import-
antly, this change is comparable to that seen at 24 months
with IMRT, proton therapy and brachytherapy, − 5.1, −4.1
and −6.0 respectively [8,9].Conclusions
SBRT for clinically localized prostate cancer was well tol-
erated with UI rates comparable to conventionally frac-
tionated external radiotherapy and brachytherapy. MoreTable 6 Correlation between urinary incontinence bother
and urinary incontinence definition at three years post-SBRT
No problem Small problem Moderate-big
problem
Leak > Once/day 0.0% 33.3% 66.7%
Frequent dribbling 20.0% 20.0% 60.0%
Any pad usage 5.9% 58.8% 35.3%
EPIC UI summary
“Severe” (0-49)
0.0% 18.2% 81.8%than 90% of men who were pad-free prior to treatment
remained pad-free three years following treatment. Less
than 10% of men felt post-treatment UI was a moderate to
big problem at any time point following treatment. Longer
term follow-up is needed to confirm late effects.
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